| Name | Title | Contact Details |
|---|
Geneos is developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells.
Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes.
Novacam Technologies, Inc. is a Pointe-Claire, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pionyr Immunotherapeutics discovers and develops first-in-class biologic drugs that fine-tune natural immune responses to increase immune defenses for diseases such as cancer, or to dampen immune responses in autoimmune diseases.
FASgen is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.